FDA Advises of Adverse Effects from New Cholesterol Drugs

FDA Advises of Adverse Effects from New Cholesterol Drugs

The FDA also asked that the companies inform regulators of the feasibility of including neurocognitive testing in at least a subset of patients in one or more of their clinical trials, according to the filings. Dr. Schleifer said Regeneron and Sanofi

6
Like
Save

Comments

Write a comment

*